Healthcare >> Analyst Interviews >> April 21, 2017
Downturn in Biotech Creates Opportunities for Investors to Realize Superior Gains
Keith A. Markey, Ph.D., is a Scientific Director of Biotechnology at Griffin Securities, Inc. Dr. Markey is an Equities Analyst with more than 25 years of experience. In addition to conducting research, he provides advisory services on partnering/licensing, mergers/acquisitions and financing for companies in the biotechnology, pharmaceutical and medical device sectors. Previously, Dr. Markey held various managerial positions in the Value Line Research Department, supporting the Value Line Investment Survey with original research and by selecting stocks for coverage. He began his career as a biochemist, working in the fields of endocrinology and neuroscience. His research, which resulted in more than 30 publications, contributed to our understanding of regulatory biochemistry and stem cell plasticity. Dr. Markey has lectured on scientific and financial subjects, and is a member of the National Association of Corporate Directors and the National Association of Science Writers. He earned a Ph.D. in neurochemistry from the University of Connecticut and an MBA in finance from the Leonard N. Stern School of Business at New York University. Profile
TWST: What, within your coverage universe, are you focusing on the most right now and why?
Dr. Markey: My coverage universe is focused on biotechnology, and in